Results 51 to 60 of about 61,606 (299)

Evaluation of hydroxyurea genotoxicity in patients with sickle cell disease

Einstein (São Paulo)
Objective To evaluate the induction of DNA damage in peripheral blood mononuclear cells of patients with sickle cell disease, SS and SC genotypes, treated with hydroxyurea.
Emanuel Almeida Moreira de Oliveira, Kenia de Assis Boy, Ana Paula Pinho Santos, Carla da Silva Machado, Cibele Velloso-Rodrigues, Pâmela Souza Almeida Silva Gerheim, Leonardo Meneghin Mendonça   +6 more
doaj   +1 more source

Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males

Haematologica, 2008
Background Recent progress in the treatment of sickle cell disease, in particular the use of hydroxyurea, has considerably modified the prognosis of this disease. Many more patients now reach reproductive age.
Isabelle Berthaut, Geoffroy Guignedoux, Frederique Kirsch-Noir, Vanina de Larouziere, Celia Ravel, Dora Bachir, Frédéric Galactéros, Pierre-Yves Ancel, Jean-Marie Kunstmann, Laurence Levy, Pierre Jouannet, Robert Girot, Jacqueline Mandelbaum   +12 more
doaj   +1 more source

Impact of Xmn1 polymorphism on hydroxyurea therapy in children with HbE-β non-transfusion dependent thalassemia: a cohort study [PDF]

Clinical and Experimental Pediatrics
Background Fetal hemoglobin (HbF) inducers, among which hydroxyurea is the most extensively used, have shifted the paradigm toward the treatment of non–transfusion-dependent thalassemia (NTDT).
Saheli Roy, Paramita Bhattacharya, Atanu Kumar Dutta, Mrinal Kanti Das   +3 more
doaj   +1 more source

Barriers to Pediatric Sickle Cell Disease Guideline Recommendations. [PDF]

, 2019
National guidelines recommend that providers counsel all patients with sickle cell anemia about hydroxyurea (HU) therapy and screen children with sickle cell anemia annually for the risk of stroke with transcranial Doppler (TCD).
Bardach, Naomi S, Cabana, Michael D, Kanter, Julie, Marsh, Anne M, Rowland, Michael, Stemmler, Peggy, Treadwell, Marsha J   +6 more
core  

Leg Ulcers in Sickle Cell Disease Patients Undergoing Hydroxyurea Therapy: Insights from Two Large Cohort Studies [PDF]

, 2023
Anoosha Habibi, Maryse Etienne‐Julan, Emmanuelle Bernit, Maria Dimopoulou, Pagona Flevari, Ersi Voskaridou, Narcisse Elenga, Estelle Jean-Mignard, Giovanna Cannas, Pablo Bartolucci   +9 more
openalex   +1 more source

Mosaic activation of the zebrafish hsp70l heat shock promoter: Implications for interpreting transgenes

Developmental Dynamics, EarlyView.
Abstract Background The promoters and enhancers of heat shock genes, such as the 1.5‐kb promoter of the zebrafish hsp70l gene, are valuable tools for temporal activation of transgenes. It has been widely purported that heat shock treatments result in ubiquitous expression of hsp70l‐driven transgenes.
Jong‐Su Park, Xiangyun Wei
wiley   +1 more source

Hydroxyurea

JAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
europepmc   +3 more sources

Treatment comparison of hydroxyurea versus ruxolitinib in essential thrombocythaemia: A matched‐cohort analysis

eJHaem
Hydroxyurea is the preferred first‐line cytoreductive treatment for high‐risk essential thrombocythaemia (ET), but many patients are intolerant or refractory to hydroxyurea. Ruxolitinib has been shown to improve symptoms in patients with ET.
Michael R. Grunwald, Ellen K. Ritchie, Elisa Rumi, Albert Assad, J. E. Hamer‐Maansson, Jingbo Yu, Tricia Kalafut, Evan Braunstein, Francesco Passamonti   +8 more
doaj   +1 more source

An assessment of the frequency of blood transfusion before and after starting hydroxyurea therapy in children of sickle cell anemia

Asian Journal of Medical Sciences, 2022
Background: Hydroxyurea therapy is a known effective and safe therapy for the treatmentof sickle cell anemia (SCA). Although it is used worldwide in our Madhya Pradesh basedsetup, it is underutilized due to economic reasons and unaware practitioners ...
Shikha Gupta , Prachi Chaudhary , Amrita Chauhan , Preeti Malpani   +3 more
doaj   +1 more source

Predictors of impending acute chest syndrome in patients with sickle cell anaemia. [PDF]

, 2020
Acute chest syndrome (ACS) is a major complication of sickle cell anaemia (SCA) and a leading cause for hospital admissions and death. We aimed to study the spectrum of clinical and laboratory features of ACS and to assess the predisposing factors and ...
Al-Busaidi, Ikhlas, Al-Salami, Bushra, Alkindi, Salam, Ballas, Samir K., Pathare, Anil, Raniga, Samir   +5 more
core   +1 more source